dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Maroto, P. |
dc.contributor.author | Apolo, Andrea B. |
dc.contributor.author | Viteri Ramirez, Santiago |
dc.contributor.author | Martin, Lidia |
dc.contributor.author | Castellano, D. |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.contributor.author | Porta, Camillo |
dc.contributor.author | Rodriguez-Antona, Cristina |
dc.date.accessioned | 2022-09-19T10:43:00Z |
dc.date.available | 2022-09-19T10:43:00Z |
dc.date.issued | 2022-07-13 |
dc.identifier.citation | Maroto P, Porta C, Capdevila J, Apolo AB, Viteri S, Rodriguez-Antona C, et al. Cabozantinib for the treatment of solid tumors: a systematic review. Ther Adv Med Oncol. 2022 Jul 13;14:1–28. |
dc.identifier.issn | 1758-8359 |
dc.identifier.uri | https://hdl.handle.net/11351/8216 |
dc.description | Cabozantinib; Carcinoma hepatocelular; Tumor sólido |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Medical Oncology;14 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Proteïnes quinases - Inhibidors - Ús terapèutic |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Protein-Tyrosine Kinases |
dc.subject.mesh | /antagonists & inhibitors |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Cabozantinib for the treatment of solid tumors: a systematic review |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/17588359221107112 |
dc.subject.decs | proteína-tirosina cinasas |
dc.subject.decs | /antagonistas & inhibidores |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1177/17588359221107 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Maroto P] Medical Oncology Services, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, Barcelona, 08025, Spain. [Porta C] Interdisciplinary Department of Medicine, University of Bari “Aldo Moro,” Bari, Italy. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Apolo AB] Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [Viteri S] UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain. [Rodriguez-Antona C] Antona National Cancer Research Center, Madrid, Spain. [Martin L] Ipsen Pharma, Barcelona, Spain. [Castellano D] Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain |
dc.identifier.pmid | 35847482 |
dc.identifier.wos | 000827721700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |